DOCSLIB.ORG

AGC Building Trades Welfare Plan V. Forest Laboratories

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AGC Building Trades Welfare Plan V. Forest Laboratories Case 1:20-cv-01799 Document 1 Filed 02/28/20 Page 1 of 6 81,7('67$7(6',675,&7&2857 6287+(51',675,&72)1(:<25. $)RI/±$*&%8,/',1*75$'(6:(/)$5( 3/$1LQGLYLGXDOO\DQGRQEHKDOIRILWVHOIDQGDOORWKHUV VLPLODUO\VLWXDWHG 3ODLQWLII &$1RBBBBBBBBBBBBBBBBB Y 127,&(2)5(029$/ )25(67/$%25$725,(6//& 'HIHQGDQW -85<75,$/'(0$1'(' 72 7+( &/(5. 2) 7+( 81,7(' 67$7(6 ',675,&7 &2857 )25 7+( 6287+(51',675,&72)1(:<25. 3/($6( 7$.( 127,&( WKDW SXUVXDQW WR 86& DQG 'HIHQGDQW )RUHVW /DERUDWRULHV //& ³)RUHVW´ KHUHE\ LQYRNHV WKLV &RXUW¶V MXULVGLFWLRQ DQG UHPRYHV WKH DFWLRQ WLWOHG $) RI / ± $*& %XLOGLQJ 7UDGHV :HOIDUH 3ODQ Y )RUHVW /DERUDWRULHV//&FXUUHQWO\SHQGLQJLQWKH6XSUHPH&RXUWRIWKH6WDWHRI1HZ<RUN1HZ<RUN &RXQW\&RPPHUFLDO'LYLVLRQ,QGH[1R WKH³6WDWH$FWLRQ´ WRWKH8QLWHG6WDWHV 'LVWULFW&RXUWRIWKH6RXWKHUQ'LVWULFWRI1HZ<RUN 5HPRYDOLVDSSURSULDWHIRUWKHIROORZLQJUHDVRQV 67$7(0(172)7+(&$6( , 3URFHGXUDO%DFNJURXQG 2Q)HEUXDU\SODLQWLII$)RI/±$*&%XLOGLQJ7UDGHV:HOIDUH3ODQ ³3ODLQWLII´ ILOHGWKLV6WDWH$FWLRQLQWKH6XSUHPH&RXUWRIWKH6WDWHRI1HZ<RUN1HZ<RUN &RXQW\&RPPHUFLDO'LYLVLRQ Case 1:20-cv-01799 Document 1 Filed 02/28/20 Page 2 of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±$*&%XLOGLQJ7UDGHV:HOIDUH 3ODQ 3ODLQWLIIDOOHJHVWKDW³3ODLQWLII$)RI/$*&%XLOGLQJ7UDGHV:HOIDUH3ODQ LVDVHOILQVXUHGKHDOWKDQGZHOIDUHEHQHILWSODQZLWKLWVSULQFLSDOSODFHRIEXVLQHVVLQ0RELOH $ODEDPD´([DW 7KHUHLVRQHGHIHQGDQWLQWKLVDFWLRQ)RUHVW/DERUDWRULHV//& Case 1:20-cv-01799 Document 1 Filed 02/28/20 Page 3 of 6 )RUHVW /DERUDWRULHV //& PHUJHG ZLWK DQG LQWR $OOHUJDQ 6DOHV //& ZKRVH DGGUHVVLV*LUDOGD)DUPV0DGLVRQ1HZ-HUVH\$OOHUJDQ6DOHV//&¶VPHPEHUVDUH FLWL]HQVRI&DOLIRUQLDDQG'HODZDUH ,,, $PRXQWLQ&RQWURYHUV\ 3ODLQWLII DOOHJHV WKDW ³)RUHVW¶V XQODZIXO WDFWLFV WR SUHYHQW RUGHOD\DOHVV H[SHQVLYHJHQHULFYHUVLRQRI1DPHQGD,5IURPWLPHO\HQWHULQJWKHPDUNHWUHVXOWHGLQGDPDJHV RIRYHUELOOLRQWRFRQVXPHUVDQGWKLUGSDUW\SD\RUVZKRSXUFKDVHGWKHGUXJ´([DW 68%-(&70$77(5-85,6',&7,21$1'%$6,6)255(029$/ , 5HPRYDO-XULVGLFWLRQDQG9HQXH 5HPRYDO RI WKLV DFWLRQ IURP WKH 6XSUHPH &RXUW RI WKH 6WDWH RI 1HZ <RUN LV SURSHUXQGHU86& D EHFDXVHWKLV&RXUWZRXOGKDYHKDGRULJLQDOMXULVGLFWLRQRIWKH DFWLRQRQWKHEDVLVRIGLYHUVLW\RIFLWL]HQVKLSKDGWKHDFWLRQRULJLQDOO\EHHQEURXJKWLQWKLV&RXUW XQGHUWKH&ODVV$FWLRQ)DLUQHVV$FWRI ³&$)$´ 86& G E &$)$H[WHQGVIHGHUDOMXULVGLFWLRQWRDOOSXWDWLYHFODVVDFWLRQVLQZKLFK D WKHUH DUHRQHKXQGUHGRUPRUHPHPEHUVRIWKHSURSRVHGFODVV E WKHUHLVPLQLPDOGLYHUVLW\PHDQLQJ DWOHDVWRQHPHPEHURIWKHSURSRVHGFODVVLVDFLWL]HQRIDVWDWHGLIIHUHQWIURPDQ\GHIHQGDQWDQG F WKH DJJUHJDWHG FODLPV RI WKH LQGLYLGXDO FODVV PHPEHUV H[FHHG WKH VXP RU YDOXH RI 6HH 86& G DQG 7KLV DFWLRQ VDWLVILHV DOO RI WKHVH UHTXLUHPHQWV 9HQXH IRU WKLV UHPRYDO LV DSSURSULDWH SXUVXDQW WR 86& D EHFDXVH WKLV &RXUW¶V MXULVGLFWLRQ HPEUDFHV WKH SODFH ZKHUH WKH 6WDWH $FWLRQ LV SHQGLQJ²WKH 6XSUHPH &RXUWRIWKH6WDWHRI1HZ<RUN1HZ<RUN&RXQW\&RPPHUFLDO'LYLVLRQ Case 1:20-cv-01799 Document 1 Filed 02/28/20 Page 4 of 6 ,, &$)$-XULVGLFWLRQ $ 1XPEHURI3XWDWLYH&ODVV0HPEHUV 3ODLQWLII DOOHJHV WKDW WKHUH DUH ³KXQGUHGV RI WKRXVDQGV LI QRWPLOOLRQVRI FRQVXPHUVDQGWKRXVDQGVRIWKLUGSDUW\SD\RUV´LQWKHSXWDWLYHFODVV([DW % 0LQLPDO'LYHUVLW\RI&LWL]HQVKLS 5HPRYDO LV SURSHU XQGHU 86& D EHFDXVH WKH &RXUW KDV RULJLQDO MXULVGLFWLRQ RYHU WKLV FODVV DFWLRQ EDVHG RQ PLQLPDO GLYHUVLW\ RI FLWL]HQVKLS XQGHU 86& G $FRUSRUDWLRQLV³GHHPHGWREHDFLWL]HQRIHYHU\6WDWHDQGIRUHLJQVWDWHE\ZKLFK LW KDV EHHQ LQFRUSRUDWHG DQG RI WKH 6WDWH RU IRUHLJQ VWDWH ZKHUH LW KDV LWV SULQFLSDO SODFH RI EXVLQHVV´86& F ³>$@OLPLWHGOLDELOLW\FRPSDQ\WDNHVWKHFLWL]HQVKLSRIHDFKRILWVPHPEHUV´ %D\HULVFKH/DQGHVEDQNY$ODGGLQ&DSLWDO0JPW//&)G G&LU 3ODLQWLII¶VSULQFLSDOSODFHRIEXVLQHVVLV0RELOH$ODEDPDDQGWKXV3ODLQWLIILVD FLWL]HQRI$ODEDPD:KHWKHU3ODLQWLIILVDFLWL]HQRIDQ\RWKHU6WDWHLVXQNQRZQWR)RUHVW )RUHVWLVDFLWL]HQRI&DOLIRUQLDDQG'HODZDUH 7KHUHLVGLYHUVLW\DVUHTXLUHGE\86& G EHFDXVH3ODLQWLIILV³D FLWL]HQRID6WDWHGLIIHUHQW´IURP)RUHVW)XUWKHU3ODLQWLIIDOOHJHVWKDWWKHUHDUHSXWDWLYHFODVV PHPEHUVDFURVVWKH8QLWHG6WDWHVDQGLWV7HUULWRULHV³H[FHSW,QGLDQDDQG2KLR´([DW & $PRXQWLQ&RQWURYHUV\ %HFDXVH 3ODLQWLII DOOHJHV PRUH WKDQ ELOOLRQ LQ GDPDJHV WKH DPRXQW LQ FRQWURYHUV\ DOOHJHG E\ 3ODLQWLII VDWLVILHV WKH DPRXQW LQ FRQWURYHUV\ UHTXLUHPHQW UHTXLUHGXQGHU86& G Case 1:20-cv-01799 Document 1 Filed 02/28/20 Page 5 of 6 &21&/86,21 :+(5()25()RUHVWUHPRYHVWKHPDWWHUFDSWLRQHG$)RI/±$*&%XLOGLQJ7UDGHV :HOIDUH3ODQY)RUHVW/DERUDWRULHV//&,QGH[1RIURPWKH6XSUHPH&RXUWRI WKH6WDWHRI1HZ<RUN1HZ<RUN&RXQW\&RPPHUFLDO'LYLVLRQWRWKH8QLWHG6WDWHV'LVWULFW &RXUWRIWKH6RXWKHUQ'LVWULFWRI1HZ<RUN 'DWHG)HEUXDU\ 5HVSHFWIXOO\VXEPLWWHG V0DUWLQ07RWR 0DUWLQ07RWR .ULVWHQ2¶6KDXJKQHVV\ :+,7( &$6(//3 $YHQXHRIWKH$PHULFDV 1HZ<RUN1HZ<RUN 7HOHSKRQH &RXQVHOIRU'HIHQGDQW)RUHVW /DERUDWRULHV//& Case 1:20-cv-01799 Document 1 Filed 02/28/20 Page 6 of 6 &(57,),&$7(2)6(59,&( , KHUHE\ FHUWLI\ WKDW RQ)HEUXDU\ , FDXVHG WUXH DQG FRUUHFW FRSLHV RI WKLV 1RWLFH RI 5HPRYDODQGDOOUHODWHGGRFXPHQWVWREHVHUYHGE\860DLOSRVWDJHSUHSDLGDQG(OHFWURQLF 0DLOXSRQ 0LFKDHO0%XFKPDQ 7KLUG$YHQXHWK)ORRU 1HZ<RUN1< PEXFKPDQ#PRWOH\ULFHFRP $WWRUQH\IRUWKH3ODLQWLII V'DQLHO-*URVVEDXP 'DQLHO-*URVVEDXP Case 1:20-cv-01799 Document 1-1 Filed 02/28/20 Page 1 of 57 ([KLELW '*-&%/&8:03,$06/5:$-&3,1. */%&9/0 /:4$&'%0$/0 Case 1:20-cv-01799 Document 1-1 Filed 02/28/20 Page3&$&*7&%/:4$&' 2 of 57 SUPREME COURT OF THE STATE OF NEW YORK NEW YORK COUNTY: COMMERCIAL DIVISION A.F. of L. – A.G.C. BUILDING TRADES WELFARE PLAN, individually and on behalf of itself and all others similarly situated, Index No: Plaintiff, v. SUMMONS FOREST LABORATORIES, LLC, Defendant. To the above named Defendant Forest Laboratories, LLC 909 Third Avenue New York, New York 10022 YOU ARE HEREBY SUMMONED and required to serve upon plaintiffs’ attorney, at the address stated below, an answer to the attached complaint within twenty (20) days after the service of this summons, exclusive of the day of service, or within thirty (30) days after the service is complete if this summons is not personally delivered to you within the State of New York; and in case of your failure to answer, judgment will be taken against you by default for the relief demanded in the complaint. The basis of venue is Defendant’s principal place of business at 909 Third Avenue, New York, New York. Dated: New York, New York February 7, 2020 MOTELY RICE LLC By: /s/ Michael M. Buchman Michael M. Buchman 777 Third Avenue, 27th Floor New York, NY 10017 Telephone: (212) 577-0040 Facsimile: (212) 577-0054 [email protected] Attorneys for the Plaintiff PG '*-&%/&8:03,$06/5:$-&3,1. */%&9/0 /:4$&'%0$/0 Case 1:20-cv-01799 Document 1-1 Filed 02/28/20 Page3&$&*7&%/:4$&' 3 of 57 SUPREME COURT OF THE STATE OF NEW YORK NEW YORK COUNTY: COMMERCIAL DIVISION A.F. of L. – A.G.C. BUILDING TRADES WELFARE PLAN, individually and on behalf of itself and all others similarly situated, Index No: Plaintiff, v. CLASS ACTION COMPLAINT FOREST LABORATORIES, LLC, JURY TRIAL DEMANDED Defendant. Plaintiff A.F. of L. – A.G.C. Building Trades Welfare Plan (“Plaintiff”), on behalf itself and all others similarly situated, brings this antitrust, consumer protection and unjust enrichment class action seeking damages arising from Defendant Forest Laboratories, LLC’s anticompetitive scheme to maintain its monopoly over the $1.5 billion per year market for its blockbuster Alzheimer’s drug Namenda IR. Forest’s unlawful tactics to prevent or delay a less expensive generic version of Namenda IR from timely entering the market resulted in damages of over $2 billion to consumers and third-party payors who purchased the drug. Forest Laboratories LLC is headquartered at 909 Third Avenue, New York New York. PRELIMINARY STATEMENT 1. This class action is against Forest Laboratories LLC1 (“Forest” or Defendant”) concerning its anticompetitive scheme to prevent or delay a less expensive generic version of Namenda IR from entering its $1.5 billion dollar market. Namenda IR is a U.S. Food & Drug Administration (“FDA”) approved oral medication prescribed by physicians to treat moderate to severe dementia in Alzheimer’s patients. After approval from the FDA in October 2003, Forest 1 Forest was acquired by, and became a wholly-owned subsidiary of, Actavis, plc on July 1, 2014; Actavis, plc began operating under the name Allergan, plc on or about June 15, 2015. PG '*-&%/&8:03,$06/5:$-&3,1. */%&9/0 /:4$&'%0$/0 Case 1:20-cv-01799 Document 1-1 Filed 02/28/20 Page3&$&*7&%/:4$&' 4 of 57 launched Namenda IR in the U.S. market in January 2004. 2. Several generic companies filed Abbreviated New Drug Applications (“ANDAs”) with the FDA seeking permission to manufacture, market, and sell an AB-rated generic version of Namenda IR in the United States. The Hatch-Waxman Act, enacted in 1984, provides generic companies with an abbreviated process to quickly and cost effectively receive FDA approval to come to market. The
Load more

Recommended publications
  • Biocentury 8.15.16
    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • Malek V. Abbvie, Inc. Et
    Case 1:20-cv-07492-LJL Document 1 Filed 09/12/20 Page 1 of 73 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK RICHARD MALEK, on his own behalf and all others similarly situated, Civil Action No. __________ Plaintiff, v. CLASS ACTION COMPLAINT ABBVIE INC., ALLERGAN, INC., ALLERGAN SALES, LLC, ALLERGAN USA, DEMAND FOR JURY TRIAL INC., FOREST LABORATORIES, INC., FOREST LABORATORIES HOLDINGS, LTD., FOREST LABORATORIES IRELAND, LTD., and FOREST LABORATORIES, LLC, Defendants. Plaintiff Richard Malek (“Plaintiff”), on behalf of himself and all others similarly situated, brings this Class Action Complaint against AbbVie, Inc. (“AbbVie”); Allergan, Inc., Allergan Sales, LLC, and Allergan USA, Inc. (collectively, “Allergan”); and Forest Laboratories, Inc., Forest Laboratories Holdings, Ltd., Forest Laboratories, LLC, and Forest Laboratories Ireland Ltd. (collectively, “Forest”) (together with AbbVie and Allergan, “Defendants”) for Defendants’ violations of federal and state antitrust, consumer protection and unjust enrichment laws concerning the pharmaceutical drug Bystolic® (nebivolol hydrochloride) (“Bystolic”). Based upon the investigation of counsel, information and belief, and personal knowledge, Plaintiff alleges as follows: 1 CLASS ACTION COMPLAINT Case 1:20-cv-07492-LJL Document 1 Filed 09/12/20 Page 2 of 73 INTRODUCTION 1. This is an antitrust action seeking treble damages and declaratory and injunctive relief under state antitrust, consumer protection and unjust enrichment law, and federal antitrust law, as a result of Defendants’ unlawful exclusion of generic substitutes for the branded drug Bystolic. Bystolic contains the active pharmaceutical ingredient nebivolol hydrochloride or nebivolol HCl and is an important cardiovascular prescription drug used to treat high blood pressure. It is commonly referred to as a “beta blocker” or a beta-adrenergic blocking agent that reduces blood pressure.
    [Show full text]
  • Rebateable Manufacturers
    Rebateable Labelers – July 2021 Manufacturers are responsible for updating their eligible drugs and pricing with CMS. Montana Healthcare Programs will not pay for an NDC not updated with CMS. Note: Some manufacturers on this list may have some NDCs that are covered and others that are not. Manufacturer ID Manufacturer Name 00002 ELI LILLY AND COMPANY 00003 E.R. SQUIBB & SONS, LLC. 00004 HOFFMANN-LA ROCHE 00006 MERCK & CO., INC. 00007 GLAXOSMITHKLINE 00008 WYETH PHARMACEUTICALS LLC, 00009 PHARMACIA AND UPJOHN COMPANY LLC 00013 PFIZER LABORATORIES DIV PFIZER INC 00015 MEAD JOHNSON AND COMPANY 00023 ALLERGAN INC 00024 SANOFI-AVENTIS, US LLC 00025 PFIZER LABORATORIES DIV PFIZER INC 00026 BAYER HEALTHCARE LLC 00032 ABBVIE INC. 00037 MEDA PHARMACEUTICALS, INC. 00039 SANOFI-AVENTIS, US LLC 00046 WYETH PHARMACEUTICALS INC. 00049 ROERIG 00051 ABBVIE INC 00052 ORGANON USA INC. 00053 CSL BEHRING L.L.C. 00054 HIKMA PHARMACEUTICAL USA, INC. 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00065 ALCON LABORATORIES, INC. 00068 AVENTIS PHARMACEUTICALS 00069 PFIZER LABORATORIES DIV PFIZER INC 00071 PARKE-DAVIS DIV OF PFIZER 00074 ABBVIE INC 00075 AVENTIS PHARMACEUTICALS, INC. 00078 NOVARTIS 00085 SCHERING CORPORATION 00087 BRISTOL-MYERS SQUIBB COMPANY 00088 AVENTIS PHARMACEUTICALS 00093 TEVA PHARMACEUTICALS USA, INC. 00095 BAUSCH HEALTH US, LLC Page 1 of 19 Manufacturer ID Manufacturer Name 00096 PERSON & COVEY, INC. 00113 L. PERRIGO COMPANY 00115 IMPAX GENERICS 00116 XTTRIUM LABORATORIES, INC. 00121 PHARMACEUTICAL ASSOCIATES, INC. 00131 UCB, INC. 00132 C B FLEET COMPANY INC 00143 HIKMA PHARMACEUTICAL USA, INC. 00145 STIEFEL LABORATORIES, INC, 00168 E FOUGERA AND CO. 00169 NOVO NORDISK, INC. 00172 TEVA PHARMACEUTICALS USA, INC 00173 GLAXOSMITHKLINE 00178 MISSION PHARMACAL COMPANY 00185 EON LABS, INC.
    [Show full text]
  • Important Transaction and Tax Information Regarding the Exchange Transaction of Pharmaceutical Holdrs Trust Into Shares of Market Vectors Pharmaceutical Etf
    IMPORTANT TRANSACTION AND TAX INFORMATION REGARDING THE EXCHANGE TRANSACTION OF PHARMACEUTICAL HOLDRS TRUST INTO SHARES OF MARKET VECTORS PHARMACEUTICAL ETF For electing owners (“Exchange Participants”) of Pharmaceutical HOLDRS Trust (“PPH HOLDRS”), units of PPH HOLDRS were exchanged on December 20, 2011 for shares of Market Vectors Pharmaceutical ETF. For each PPH HOLDR receipt validly tendered, Exchange Participants received 1 share of Market Vectors Pharmaceutical ETF. This exchange was effected through a series of transfers and rebalance transactions (sales transactions in certain securities underlying the PPH HOLDRS and purchase transactions in new securities for exchange into Market Vectors Pharmaceutical ETF). These transactions were authorized by the Exchange Participant and executed on their behalf. As a result of the rebalance transactions, part of this exchange may result in a taxable event and cost basis adjustments to the Exchange Participant. Provided is a breakdown of the exchange transactions and tax implications based on a ‘PPH HOLDR trading unit” (100 PPH HOLDRS receipts) 1. For each PPH HOLDR Trading Unit tendered, BNY Mellon Shareowner Services as Exchange Agent for the exchange offer, delivered the following securities per PPH HOLDR Trading Unit to BNY ConvergEx Execution Solutions LLC (“ConvergEx”), acting in its capacity transition manager in connection with the exchange offer. The total value of these securities transferred per PPH HOLDR Trading Unit, based on the December 20, 2011 market close, was $7,191.63.
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 28, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2016 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth, N. J. 07033 (908) 740-4000 Incorporated in New Jersey I.R.S. Employer Identification No. 22-1918501 Securities Registered pursuant to Section 12(b) of the Act: Name of Each Exchange Title of Each Class on which Registered Common Stock ($0.50 par value) New York Stock Exchange 1.125% Notes due 2021 New York Stock Exchange 0.500% Notes due 2024 New York Stock Exchange 1.875% Notes due 2026 New York Stock Exchange 2.500% Notes due 2034 New York Stock Exchange 1.375% Notes due 2036 New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2017: 2,745,571,067. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2016 based on closing price on June 30, 2016: $159,263,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
    [Show full text]
  • Milnacipran Hcl) Tablets Prior to Initiating Treatment with Savella and Periodically Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION have been reported with SNRIs and SSRIs. Discontinue Savella These highlights do not include all the information needed to and initiate supportive treatment (5.2, 7). use Savella safely and effectively. See full prescribing Elevated blood pressure and heart rate: Cases have been information for Savella. reported with Savella. Monitor blood pressure and heart rate SAVELLA® (milnacipran HCl) Tablets prior to initiating treatment with Savella and periodically Initial U.S. Approval: 2009 throughout treatment (5.3, 5.4). Seizures: Cases have been reported with Savella therapy. WARNING: SUICIDALITY AND ANTIDEPRESSANT Prescribe Savella with care in patients with a history of seizure DRUGS disorder (5.5). See full prescribing information for complete boxed warning. Hepatotoxicity: More patients treated with Savella than with placebo experienced mild elevations of ALT and AST. Rarely, Increased risk of suicidal ideation, thinking, and behavior fulminant hepatitis has been reported in patients treated with in children, adolescents, and young adults taking Savella. Avoid concomitant use of Savella in patients with antidepressants for major depressive disorder (MDD) and substantial alcohol use or chronic liver disease (5.6). other psychiatric disorders. Savella is not approved for use Discontinuation: Withdrawal symptoms have been reported in in pediatric patients (5.1). patients when discontinuing treatment with Savella. A gradual dose reduction is recommended (5.7). ---------------------INDICATIONS AND USAGE--------------------- Abnormal Bleeding: Savella may increase the risk of bleeding Savella® is a selective serotonin and norepinephrine reuptake events. Caution patients about the risk of bleeding associated inhibitor (SNRI) indicated for the management of fibromyalgia (1). with the concomitant use of Savella and NSAIDs, aspirin, or Savella is not approved for use in pediatric patients (5.1).
    [Show full text]
  • Sitting Down with Christian Schneider, Director Of
    APRIL 2016 # 18 Upfront In My View Business Sitting Down With Reducing the manufacturing Why pharma must address Can small biotechs bear the Christian Schneider, costs of gene therapies environmental discharges burden of innovation? Director of NIBSC 10 17 48 – 49 50 – 51 www.themedicinemaker.com We’re Backing Batch Pharma is investing in continuous manufacturing for the future, but batch-based processing is the here and now! From powder to coated tablet and from R&D to full-scale Designed with integration in mind, you can select from a variety manufacturing, no other supplier offers such a comprehensive of standard process modules to suit your project needs. Plus, as range of batch-based technologies for oral solid dosage form containment experts, we not only offer the largest portfolio of production. Whatever your application, no matter how contained processing solutions, we can assist with the selection challenging, GEA’s powder handling, granulating, drying, process and optimise your entire production line, making it compression and coating solutions will meet and exceed efficient, safe and cost-effective. Contact [email protected] your individual requirements. today for more information or talk to an expert at POWTECH (booth 3A-237) or INTERPHEX (booth 2421). gea_batch_ad_medicine_maker.indd 2 24/03/2016 15:00 Online this Month Controlling Crystallization lecturer in the Department of Chemical Engineering at Imperial College London, We all know that crystallization is crucial UK, and focuses on understanding the in the pharma industry when it comes role of surface properties in particle to manufacturing active pharmaceutical engineering. Recently, he has examined ingredients (APIs) – and on page 12 of the feasibility of establishing template- We’re Backing Batch this issue you can read a snapshot about induced polymorphic domains for API the fascinating work from Jerry Heng crystallization.
    [Show full text]
  • Policy & Practice
    DECEMBER 2010 • WWW.ECARDIOLOGYNEWS.COM PRACTICE TRENDS 47 POLICY & PRACTICE depressant Paxil CR, the diabetes med- enue, costs, and staffing and found that ication Avandamet, and the anti-infection it correlated with $50,000 more net rev- WANT MORE HEALTH REFORM NEWS? ointment Bactroban. The complaint al- enue per full-time physician in practices SUBSCRIBE TO OUR PODCAST – SEARCH leged that the drugmaker failed to prove that were not owned by hospitals or in- ‘POLICY & PRACTICE’ IN THE ITUNES STORE that Bactroban and Kytril were not con- tegrated delivery systems. The wired taminated with microorganisms. practices reported $105,591 higher ex- AHA Merges Guidelines compared with only 58 men per 1,000 ad- GlaxoSmithKline will pay the federal penses per full-time physician, but had The American Heart Association has missions. The data come from the government $600 million, and a whistle- significantly more revenue per physi- combined its quality improvement pro- agency’s Trends in Hospital Risk-Adjust- blower will receive $96 million for hav- cian, the association said. “These data in- grams on cardiopulmonary resuscita- ed Mortality for Selected Diagnoses by Pa- ing tipped the federal government to dicate that there are financial benefits to tion and postresuscitation care. The tient Subgroups, 2000-2007. the manufacturing issues. The states are practices that implement an EHR sys- melding of the association’s National eligible to receive up to $163 million tem,” Dr. William Jessee, the associa- Registry of CardioPulmonary Resusci- Red Flag for A Fib Drug from GSK. The complaint alleged that tion’s president and CEO, said in a state- tation program with its Get With the The Institute for Safe Medication Practices the company knowingly caused false ment.
    [Show full text]
  • Biopharma Boom Fosters Deal Spree
    Biopharma boom fosters deal spree Valuations and volume are up in a buoyant year for biopharmaceutical dealmaking. From tax inversions to gene therapy and, of course, immuno-oncology, 2014 and early 2015 featured plenty of wheeling and dealing. BY CHRIS MORRISON Table 1. Top 10 acquisitions announced in 2014. lthough it was a record year for biophar- Deal Value maceutical dealmaking—a year that A included more than $200 billion worth Actavis acquires Allergan $66 billion of mergers and acquisitions—one could argue Actavis acquires Forest Laboratories $22.8 billion that the most interesting and dramatic deals reportsBCIQ; Company of 2014 were the ones that never happened. Merck & Co. acquires Cubist Pharmaceuticals $9.5 billion Those almost-deals, mega-mergers in hot pur- Roche acquires Intermune $8.3 billion suit of corporate-friendly tax climates to drive margin expansion of the combined entities, Mallinckrodt acquires Questcor $5.7 billion were eventually thwarted by recalcitrant targets Merck & Co. acquires Idenix $3.7 billion or the slow-to-materialize posturing of the US Treasury. They were massive and oxygen con- Otsuka acquires Avanir $3.5 billion suming, and their failures set up rebound deals that, though smaller, are no less intriguing. Forest Laboratories acquires Aptalis $2.9 billion The failed $117 billion and $53 billion Endo acquires Auxilium $2.6 billion takeovers of AstraZeneca by Pfizer and Shire by AbbVie, respectively, tell only part of the Johnson & Johnson acquires Alios $1.75 billion story of 2014’s massive dealmaking binge. Data courtesy of Biocentury’s BCIQ Database. All acquisitions are of biopharma companies with patented prescription pharmaceutical focus (excludes devices, diagnostics, OTC, generic-only deals).
    [Show full text]